NRG1 and myeloid sarcoma: The inclusion of potentially misdiagnosed cases adds complexity to the findings, and the absence of treatment-naïve MS and NMO patients precluded analysis of the lncRNA Ftx/miR-382-5p/NRG1 axis across treatment groups.